Regeneron Pharmaceuticals, Inc. (REGN) announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, to acquire full development and commercialization rights to its pipeline of investigational immune cell therapies. Philip Gregory, currently the Chief Scientific Officer of 2seventy bio, will be appointed Senior Vice President and Head of Regeneron Cell Medicines.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,037 USD | +0.97% | +3.35% | +18.02% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.02% | 112B | |
+18.15% | 124B | |
+4.83% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B | |
+106.26% | 10.31B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals, Inc. Appoints Philip Gregory as Senior Vice President and Head of Regeneron Cell Medicines